References

Collins, F. S. 2011. Reengineering translational science: The time is right. Science Translational Medicine 3(90):90cm17.

Eichler, H. G., B. Bloechl-Daum, E. Abadie, D. Barnett, F. König, and S. Pearson. 2010. Relative efficacy of drugs: An emerging issue between regulatory agencies and third-party payers. Nature Reviews Drug Discovery 9(4):277–291.

FDA (Food and Drug Administration). 2011. Advancing regulatory science at FDA: A strategic plan, http://www.fda.gov/downloads/ScienceResearch/SpecialTopics/RegulatoryScience/UCM268225.pdf (accessed June 18, 2012).

Goldman, M. 2012. The Innovative Medicines Initiative: A European response to the innovation challenge. Clinical Pharmacology and Therapeutics 9(3):418–425.

Herper, M. 2012. The truly staggering cost of inventing new drugs. Forbes, February 10.

Hewitt, J., J. D. Campbell, and J. Cacciotti. 2011. Beyond the shadow of a drought: The need for a new mindset in pharma R&D. Oliver Wyman, http://www.oliverwyman.com/media/OW_EN_HLS_PUBL_2011_Beyond_the_Shadow_of_a_Drought%283%29.pdf (accessed June 19, 2012).

Huang, R., N. Southall, Y. Wang, A. Yasgar, P. Shinn, A. Jadhav, D. T. Nguyen, and C. P. Austin. 2011. The NCGC pharmaceutical collection: A comprehensive resource of clinically approved drugs enabling repurposing and chemical genomics. Science Translational Medicine 3(80):80ps16.

IOM (Institute of Medicine). 2011. Establishing precompetitive collaborations to stimulate genomics-driven product development: Workshop summary. Washington, DC: The National Academies Press.

Kris, M. G., B. E. Johnson, D. J. Kwiatkowski, A. J. Iafrate, I. I. Wistuba, S. L. Aronson, J. A. Engelman, Y. Shyr, F. R. Khuri, C. M. Rudin, E. B. Garon, W. Pao, J. H. Schiller, E. B. Haura, K. Shirai, G. Giaccone, L. D. Berry, K. Kugler, J. D. Minna, and P. A. Bunn. 2011. Identification of driver mutations in tumor specimens from 1,000 patients with lung adenocarcinoma: The NCI’s Lung Cancer Mutation Consortium (LCMC). Journal of Clinical Oncology 29(Suppl 18):CRA7506. http://meeting.ascopubs.org/cgi/content/abstract/29/18_suppl/CRA7506?sid=582aea71-36a2-4117-96c7-9e783602272f  (accessed June 19, 2012).



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement



Below are the first 10 and last 10 pages of uncorrected machine-read text (when available) of this chapter, followed by the top 30 algorithmically extracted key phrases from the chapter as a whole.
Intended to provide our own search engines and external engines with highly rich, chapter-representative searchable text on the opening pages of each chapter. Because it is UNCORRECTED material, please consider the following text as a useful but insufficient proxy for the authoritative book pages.

Do not use for reproduction, copying, pasting, or reading; exclusively for search engines.

OCR for page 55
References Collins, F. S. 2011. Reengineering translational science: The time is right. Science Translational Medicine 3(90):90cm17. Eichler, H. G., B. Bloechl-Daum, E. Abadie, D. Barnett, F. Knig, and S. Pearson. 2010. Rela- tive efficacy of drugs: An emerging issue between regulatory agencies and third-party payers. Nature Reviews Drug Discovery 9(4):277291. FDA (Food and Drug Administration). 2011. Advancing regulatory science at FDA: A strategic plan, http://www.fda.gov/downloads/ScienceResearch/SpecialTopics/RegulatoryScience/ UCM268225.pdf (accessed June 18, 2012). Goldman, M. 2012. The Innovative Medicines Initiative: A European response to the innova- tion challenge. Clinical Pharmacology and Therapeutics 9(3):418425. Herper, M. 2012. The truly staggering cost of inventing new drugs. Forbes, February 10. Hewitt, J., J. D. Campbell, and J. Cacciotti. 2011. Beyond the shadow of a drought: The need for a new mindset in pharma R&D. Oliver Wyman, http://www.oliverwyman.com/ media/OW_EN_HLS_PUBL_2011_Beyond_the_Shadow_of_a_Drought%283%29.pdf (accessed June 19, 2012). Huang, R., N. Southall, Y. Wang, A. Yasgar, P. Shinn, A. Jadhav, D. T. Nguyen, and C. P. Austin. 2011. The NCGC pharmaceutical collection: A comprehensive resource of clini- cally approved drugs enabling repurposing and chemical genomics. Science Translational Medicine 3(80):80ps16. IOM (Institute of Medicine). 2011. Establishing precompetitive collaborations to stimulate genomics-driven product development: Workshop summary. Washington, DC: The Na- tional Academies Press. Kris, M. G., B. E. Johnson, D. J. Kwiatkowski, A. J. Iafrate, I. I. Wistuba, S. L. Aronson, J. A. Engelman, Y. Shyr, F. R. Khuri, C. M. Rudin, E. B. Garon, W. Pao, J. H. S chiller, E. B. Haura, K. Shirai, G. Giaccone, L. D. Berry, K. Kugler, J. D. Minna, and P. A. Bunn. 2011. Identification of driver mutations in tumor specimens from 1,000 patients with lung adenocarcinoma: The NCI's Lung Cancer Mutation Consortium (LCMC). Journal of Clinical Oncology 29(Suppl 18):CRA7506. http://meeting.ascopubs.org/cgi/ content/abstract/29/18_suppl/CRA7506?sid=582aea71-36a2-4117-96c7-9e783602272f (accessed June 19, 2012). 55

OCR for page 55
56 GENOME-BASED THERAPEUTICS Lillie, E. O., B. Patay, J. Diamant, B. Issell, E. J. Topol, and N. J. Schork. 2011. The N-of-1 clinical trial: The ultimate strategy for individualizing medicine? Personalized Medicine 8(2):161173. Mullard, A. 2012. FDA drug approvals. Nature Reviews Drug Discovery 11(2):9194. Munos, B. 2009. Lessons from 60 years of pharmaceutical innovation. Nature Reviews Drug Discovery 8(12):959968. NRC (National Research Council). 2011. Toward precision medicine: Building a knowledge network for biomedical research and a new taxonomy of disease. Washington, DC: The National Academies Press. Patil, S. T., L. Zhang, F. Martenyi, S. L. Lowe, K. A. Jackson, B. V. Andreev, A. S. Avedisova, L. M. Bardenstein, I. Y. Gurovich, M. A. Morozova, S. N. Mosolov, N. G. Neznanov, A. M. Reznik, A. B. Smulevich, V. A. Tochilov, B. G. Johnson, J. A. Monn, and D. D. Schoepp. 2007. Activation of mGlu2/3 receptors as a new approach to treat s chizophrenia: A randomized Phase 2 clinical trial. Nature Medicine 13(9):11021107. Paul, S. M., D. S. Mytelka, C. T. Dunwiddie, C. C. Persinger, B. H. Munos, S. R. Lindborg, and A. L. Schacht. 2010. How to improve R&D productivity: The pharmaceutical industry's grand challenge. Nature Reviews Drug Discovery 9(3):203214. Pirmohamed, M., S. James, S. Meakin, C. Green, A. K. Scott, T. J. Walley, K. Farrar, B. K. Park, and A. M. Breckenridge. 2004. Adverse drug reactions as cause of admission to hospital: Prospective analysis of 18,820 patients. British Medical Journal 329(7456):1519. Pollack, A. 2010. Awaiting the genome payoff. New York Times, June 14, B1. Ramsey, B. W., N. G. Davies, E. McElvaney, E. Tullis, S. C. Bell, P. Devnek, M. Griese, E. F. McKone, C. E. Wainwright, M. W. Konstan, R. Moss, F. Ratjen, I. Sermet-Gaudelus, S. M. Rowe, Q. Dong, S. Rodriguez, K. Yen, C. Ordoez, J. S. Elborn, and VX08-770-102 Study Group. 2011. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. New England Journal of Medicine 365(18):16631672. Riess, J. W., and H. A. Wakelee. 2012. Metastatic non-small cell lung cancer management: Novel targets and recent clinical advances. Clinical Advances in Hematology & O ncology 10(4):226234. http://www.clinicaladvances.com/article_pdfs/ho0412_reiss.pdf (accessed June 18, 2012). Rikova, K., A. Guo, Q. Zeng, A. Possemato, J. Yu, H. Haack, J. Nardone, K. Lee, C. Reeves, Y. Li, Y. Hu, Z. Tan, M. Stokes, L. Sullivan, J. Mitchell, R. Wetzel, J. Macneill, J. M. Ren, J. Yuan, C. E. Bakalarski, J. Villen, J. M. Kornhauser, B. Smith, D. Li, X. Zhou, S. P. Gygi, T. L. Gu, R. D. Polakiewicz, J. Rush, and M. J. Comb. 2007. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 131(6):11901203. Scannell, J. W., A. Blanckley, H. Boldon, and B. Warrington. 2012. Diagnosing the decline in pharmaceutical R&D efficiency. Nature Reviews Drug Discovery 11(3):191200. Sirota, M., J. T. Dudley, J. Kim, A. P. Chiang, A. A. Morgan, A. Sweet-Cordero, J. Sage, and A. T. Butte. 2011. Discovery and preclinical validation of drug indications using compendia of public gene expression data. Science Translational Medicine 3(96):96ra77. Soda, M., Y. L. Choi, M. Enomoto, S. Takada, Y. Yamashita, S. Ishikawa, S. Fujiwara, H. Watanabe, K. Kurashina, H. Hatanaka, M. Bando, S. Ohno, Y. Ishikawa, H. Aburatani, T. Niki, Y. Sohara, Y. Sugiyama, and H. Mano. 2007. Identification of the transform- ing EML4-ALK fusion gene in non-small-cell lung cancer. Nature 448(7153):561566. Spear, B. B., M. Heath-Chiozzi, and J. Huff. 2001. Clinical application of pharmacogenetics. Trends in Molecular Medicine 7(5):201204. Trusheim, M. R., E. R. Berndt, and F. L. Douglas. 2007. Stratified medicine: Strategic and economic implications of combining drugs and clinical biomarkers. Nature Reviews Drug Discovery 6(4):287293.

OCR for page 55
REFERENCES 57 Trusheim, M. R., B. Burgess, S. X. Hu, T. Long, S. D. Averbuch, A. A. Flynn, A. Lieftucht, A. Mazumder, J. Milloy, P. W. Shaw, D. Swank, J. Wang, E. R. Berndt, F. Goodsaid, and M. C. Palmer. 2011. Quantifying factors for the success of stratified medicine. Nature Reviews Drug Discovery 10(11):817833. Tufts Center for the Study of Drug Development. 2010. Personalized medicine is playing a growing role in development pipelines. Impact Reports 12(6). Wade, N. 2010. A decade later, genetic map yields few new cures. New York Times, June 12, A1.

OCR for page 55